• Bioscience technology accelerator XPhyto Therapeutics Corp. is working with development partner 3a-diagnostics GmbH to roll out its pandemic-related virus diagnostic tool for the European market planned in April
• The test solution, dubbed “Covid-ID Lab,” received European regulatory approval last month
• XPhyto’s product is designed to be portable and rapid in its response time to help decrease testing operation costs and increase convenience of use
• News reports about the COVID-19 pandemic reflect a growing optimism that vaccine, mask and distancing protocols may be helping to drive down infection rates, although the reports note the virus continues to have a deadly effect on many people
• Government and industry leaders have been looking for accurate and rapid diagnostic tools that may make it easier for travel operations and other businesses to resume robust activity despite the continued presence of the infectious virus

Vaccine distribution to millions of people and reports of declining rates of COVID-19 infection are generating optimism in the United States that the health crisis and its economic devastation are beginning to retreat before a modern medical technology assault, even as health officials continue to issue warnings that the deadly virus and its variants are still very active (https://ibn.fm/cl8Vk).

Bioscience technology accelerator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is now ready to launch its own solution for improving detection of the virus responsible for the worldwide pandemic. The company announced on March 18 that European regulatory officials have approved its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system, known more simply as “Covid-ID Lab,” as a commercial in vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus.

Covid-ID Lab was developed by XPhyto’s exclusive German diagnostics development partner, 3a-diagnostics GmbH  to be a COVID-19 testing system that is rapid, accurate and portable, granting it marketability as a product with decreased operating costs and increased convenience.

“Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” XPhyto CEO and Director Hugh Rogers stated (https://ibn.fm/Fi0Mw). “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings.”

The company announced in February that it had quickly formed a team of expert marketing leaders to launch Covid-ID Lab in anticipation of its approval under internationally agreed-on ISO 13485 quality standards. The market launch team consists of world-class clinical and pharmaceutical executives and service providers who have led company growth in the medical diagnostic industry from inception to over 500 million Euro per year in multinational sales, according to a company news release about the team’s work (https://ibn.fm/plVjO).

Sales rollout of the diagnostic tool is planned for April across Europe and official discussions about distribution and wholesale opportunities are under way with potential partners in the Middle East as well.

“We are extremely fortunate to now have a team with deep expertise in medical diagnostic product commercialization,” Rogers stated. “We are working hard to put the Company in the best possible position to execute on our business strategy.”

XPhyto also is developing an expanded portfolio of oral biosensor screening tests that will help clients detect other bacterial and viral infectious diseases, such as influenza A, group A strep, periodontitis and the H1N1 and H5N1 flu variants responsible for previous pandemics. The company is aiming for its first product launch under the portfolio in late 2021.

XPhyto has research and development operations in North America and Europe but its focus is the European market at this time.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

• BRSF is creating mobile, easy-to-use electroencephalogram (“EEG”) devices that enhance research integrity
• There is an increasing desire to understand the brain’s capabilities and harness them for healing
• Brain Scientific provides a cost-efficient, pre-gelled, disposable and wireless solution that provides the same signal quality as the traditional wired EEG

A growing consumer market for brain-computer interface (“BCI”) technology has some researchers worried about the quality of the data being collected. Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has developed wireless, portable, easy-to-use electroencephalogram (“EEG”) devices that do not compromise research integrity.

Data collected from consumer-centric, low-cost BCIs are typically not as efficient or as pristine as that retrieved from research-grade conventional wired EEGs. However, the sudden growth of this market, which reached 1.2 billion in 2019, is largely due to a rise in neuroprosthetic conditions, a growing geriatric population, and a desire to communicate and facilitate movement in paralytic patients (https://ibn.fm/31FwN). There is an increasing desire to understand the brain’s capabilities and harness them for healing. Consumers are investing in personal BCI devices to monitor their own health and wellness patterns (https://ibn.fm/XMI9e).

Thea Radüntz of the Federal Institute for Occupational Safety and Health in Berlin, Germany, published a study that compared these mobile devices, gel based and those without gel, with the traditional EEG for research-based on signal quality (https://ibn.fm/jp5kp). Her team found that the gel-based device worked much more efficiently for research while those without gel did not meet the requirements for signal quality.

Many of the BCIs on the market are not gelled so that the consumer can easily fit the product themselves. They have far fewer electrodes and are designed for the ease of the consumer rather than the researcher. Brain Scientific is different. With neurological conditions on the rise, the company provides a cost-efficient, pre-gelled, disposable and wireless solution that provides the same signal quality as the traditional wired EEG.

Brain Scientific has two FDA-cleared products: the NeuroCap(TM) and NeuroEEG(TM). These portable EEGs devices make it possible for medical professionals to collect necessary diagnostic information quickly and for researchers to better control the subjects’ environment during clinical trials. A recent collaboration with JelikaLite, a company working to increase the well-being of children living with autism, highlights the advantages of BrainScientific’s mobile next-gen solutions in clinical trials (https://ibn.fm/tgIuT).

Researchers, clinicians and others working in brain diagnostics and treatment benefit from the portable, wireless and compact NeuroEEG that works to acquire, record, transmit and display electrical brain activity for patients. It works in conjunction with the NeuroCap, a hospital-grade disposable EEG headset with 19 active channels and 22 electrodes. The device can perform rapid EEG testing and be used in any setting, medical centers or private homes.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• In an industry projected to reach $41 billion by 2025, Grapefruit is ideally positioned with disruptive topical cream
• Hourglass cream solves the problem of THC, other cannabinoids not being easily absorbable through the skin
• Proprietary system features patented microsized particles that deliver THC, wide range of cannabinoids through skin directly into bloodstream

The cannabis industry is gaining steam, with recent projections that annual legal medical and adult-use product sales could reach $41 billion by 2025 (https://ibn.fm/TLuCB). With that stunning growth as a backdrop, companies such as Grapefruit USA (OTCQB: GPFT) that are pioneering revolutionary products in the space appear to be particularly well positioned to seize the moment and experience extraordinary success as well. “History is happening before our eyes as the events of 2020 are fundamentally redefining the U.S. cannabis market and will continue to do so for years to come,” said Giadha A. DeCarcer, founder and CEO of New Frontier Data, a trusted authority in global cannabis analytics and business intel. According to a recent New Frontier Data report, “the pace and scale of growth the industry is experiencing is a compelling proof point that cannabis is evolving into a mainstream consumer category.” The report projects that the space will see compound annual growth rate (CAGR) of 21%, in the coming years, growing from $13.2 billion in 2019 to an estimated $41 billion by 2025. History is happening at Grapefruit as well. With its revolutionary, patented Hourglass(TM) time release THC+ Cannabinoid delivery cream, Grapefruit is offering a game-changing option for cannabis consumers. For the first time, cannabis enthusiasts can enjoy a full, discreet, convenient cannabis experience without touching, rolling, smoking, or vaping. Cannabinoids, including THC, no longer have to be ingested to be enjoyed. Grapefruit’s disruptive cream solves the previous problem of THC and other cannabinoids not being easily absorbable through the skin. Using Grapefruit’s proprietary delivery system, Hourglass topical cream creates a Patchless Patch(TM) on the top layer of the skin. The system features patented microsized particles that effectively delivers THC and a wide range of cannabinoids through skin topical administration. And after delivering the cannabinoids, the formula simply sloughs off the skin. Hourglass is manufactured exclusively at Grapefruit’s Coachillin facility by highly trained Grapefruit personnel and is available to the public only through Grapefruit authorized retailers. Grapefruit has packed the entire cannabis plant into its patented cream to provide users with a wide array of cannabinoids and THC to consistently deliver the desired synergistic entourage effects. Studies show that results are consistent, offering a reliable experience with every single gram of the Hourglass cream. To find out more about the company and its game-changing Hourglass time release THC+ Cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• New travel company one of SHRG’s Hapi Brand subsidiaries
• Company will be exclusive travel club focused on offering Passport to Happiness theme
• SHRG appoints industry travel veteran Jonathon McKillip as president

As part of its commitment to its brand partners and customers, Sharing Services Global (OTCQB: SHRG) will be unveiling a new travel company this year; the new service will focus on providing exclusive benefits and first-class discount travel opportunities at a level not seen before in the industry (https://ibn.fm/0G3Lx). “We have been planning to enter into this sector and consider now to be the most opportune time of all to announce this initiative,” said SHRG CEO John “JT” Thatch. “We have confidence that in the next several months people will want to start traveling again, as the current environment opens up, and we will be ready to offer the very best-in-class products and services for them to take full advantage of their travel experiences. In the near future, we will be unveiling our website, travel programs and exciting pre-launch activities that we believe will be well received by our brand partners and customers.” Sharing Services, a publicly traded company specializing in the direct-selling industry and network marketing, is launching the travel company as one of its Hapi Brand subsidiaries. According to the company, the new travel company will be presented as an exclusive travel club focused on offering a Passport to Happiness to members and customers. The company plans to differentiate itself by providing broad access to tremendous savings and exclusive benefits on a completely new level. “This is a very exciting time in the company, as we are working on multiple programs and expansion plans that will be unprecedented in this sector,” said Bo Short, CEO of Elevacity Holdings LLC, the parent of the new travel company. “I have been in direct selling for many years and have never seen an executive management team with such a long-term vision to reshape this industry and really serve its brand partners in this fashion. I’m excited and honored to be part of these new initiatives.” In addition, the company also named Jonathon McKillip as president of the travel company (https://ibn.fm/Am1sx). McKillip has more than two decades of travel experience specific to the direct-selling industry. His expertise is focused on strategic leadership that has driven profitability and progress for rapid, sustained growth for emerging companies. A proven achiever, competitor and relationship builder, McKillip excels in setting and reaching aggressive business goals and delivering bottom-line results. He is especially attuned to current business conditions with a unique insight to articulate a compelling vision and inspire teams to achieve. “We are very excited to have Jon lead our travel company especially in light of our U.S. and international growth plans,” said Thatch. “He has the direct-sales industry experience of a successful field leader and corporate executive. His leadership skills with top field leaders and his executive experience in the business make him an ideal fit.” Sharing Services Global Corporation, formerly Sharing Services Inc., is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling sector and other industries. The Sharing Services combined platform currently leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Initial shipments of rare earth bearing monazite mineral mark beginning of plans to produce mixed rare earth element (“REE”) carbonate
• Company ramping up operations for “what we believe will become a burgeoning supply chain,” says CEO
• Energy Fuels plans to commercially produce REE product at a stage more advanced than any other U.S. company

Energy Fuels (NYSE American: UUUU) (TSX: EFR) has received the first shipments of natural monazite ore at its White Mesa Mill in Utah (https://ibn.fm/SFNkh). Monazite ore is a naturally occurring mineral, rich in rare earth elements, which is currently mined as a byproduct of other metal mining. The shipments mark the beginning of UUUU’s plans to ramp up production of mixed rare earth element (“REE”) carbonate, an intermediate rare earth product, which is also the beginning of the company’s plans to increase domestic production of these vital minerals.

Energy Fuels will buy monazite from The Chemours Company operation in the state of Georgia, produce a mixed REE carbonate at its plant in Utah, and sell this product to Neo Performance Materials’ REE separation plant in Europe for production of value-added REE products available to U.S. and European manufacturers.

“Over the past few months, Energy Fuels, Neo and Chemours have quietly worked to create something very significant: a new, fully integrated, U.S.-Europe rare earth supply chain,” said Mark S. Chalmers, president and CEO of Energy Fuels. “This weekend’s shipments of monazite ore from Chemours to Energy Fuels marks the beginning of operations for what we believe will become a burgeoning supply chain.

“There is a lot of excitement building for rare earths, because they make many clean energy and advanced technologies possible, including electric vehicles, wind generation, batteries and advanced electronics,” he continued. “Today’s announcement is a key milestone as our companies create, refine, and grow a sustainable rare earth supply chain capable of supplying growing demand for clean technologies in the U.S. and Europe.”

The shipment of monazite received by Energy Fuels was produced by The Chemours Company at its Offerman Mineral Sand Plant in Georgia. Once Energy Fuels produces the REE carbonate from this monazite, the product will be advanced to REE separation, which is the next stage in the REE value chain. If successful in the coming weeks, Energy Fuels will be commercially producing an REE product at a stage more advanced than any other U.S. company.

One of the highest-value REE-bearing minerals in the world, monazite contains approximately 50% to 60% REEs, along with significant quantities of recoverable natural uranium. The substance, which is currently mined in the United States, Australia and Africa, is a key ingredient for many permanent REE magnet technologies used in electric vehicles and other advanced technologies. Monazite contains superior concentrations of neodymium (Nd), praseodymium (Pr) and “heavy” rare earths needed for many clean energy and advanced technologies.

Although Energy Fuels is committed to its entry into the REE sector, the company also remains committed to maintaining its position as the leading U.S. producer of uranium and vanadium. In fact, the company expects to recover the uranium in the monazite ore, which will be used as fuel for clean, carbon-free nuclear energy. Energy Fuels is also continuing to evaluate constructing value-added U.S. rare earth separation and other capabilities at its facility in Utah in the next couple of years order to capture the full value of the REE supply chain.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• PLTXF commits to use green packaging; customers can recycle, reuse PlantX packaging
• Company working to mitigate packaging waste that ends up in landfills
• PlantX will be participating in carbon off-setting initiatives

In line with its mission of providing a healthy lifestyle options in the most environmentally friendly way possible, PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has announced new green packaging and sustainability initiatives designed to reduce the company’s carbon footprint (https://ibn.fm/XDZbw). PlantX is committed to creating positive change and promoting both planetary and human health at every level. “With the evolving anthropogenic threats to the climate, today’s world has seen increasing environmental awareness and interest in planetary protection,” said PlantX founder Sean Dollinger. “People are harnessing a passion for managing our planet’s resources and this momentum is visibly manifesting in various industries.” “Sustainable packaging, also known as green packaging, is becoming an essential purchasing consideration for the modern consumer,” Dollinger continues. “By choosing to use green packaging, PlantX hopes to mitigate the polluting effects of packaging waste that ends up in landfills from its products. The increasing demand for green packaging and sustainability initiatives is becoming a crucial incentive for many high-impact businesses and manufacturers to integrate eco-friendly and ethical considerations into their operational models.” The newly announced sustainability initiatives align with PlantX’s vision to create positive change and promote both planetary and human health. The Company is already taking steps in that direction by using 100% eco-friendly packaging and marketing resources for its meal delivery services. PlantX’s green packaging is designed for customers to recycle — it is certified compostable and made from annually renewable sugarcane bagasse — or even reuse; every PlantX entrée container is microwave, dishwasher, refrigerator and freezer friendly. In addition, PlantX is partnering with Quebec-based Colder Fresher Longer, which manufactures box liners and inserts that support PLTXF’s sustainability initiatives. PlantX will use Colder Fresher Longer eco-friendly packaging to maintain products at desired temperatures throughout the shipping process while also reducing the amount of boxes needed to ship PlantX products. These new packaging standards are just the start of PlantX’s plans to adopt broader sustainability practices. The Company will also be expanding its environmental efforts by charging an eco-fee of $4.95 for certain online purchases to support recycling and disposal programs aimed at keeping certain end-of-line products out of landfills. Finally, as part of its net-zero practices, PlantX announced that it will be participating in carbon offsetting initiatives, including forest protection and renewable energy projects that offer carbon credits, which recognize when a company decreases carbon emissions. PlantX intends to work with sustainability consultants to measure the emissions reduced through offsetting activities in order to achieve recommended targets. “We are on a mission to become global leaders in promoting health and well-being for both people and the environment,” said PlantX CEO Julia Frank. “We’re including sustainability practices in a variety of ways, from using eco-friendly plantable business cards made with seed paper to making our packaging more sustainable. We’re committed to joining in the collective efforts to reduce plastic waste and help our plant-based community improve planetary health meaningfully and effortlessly.” To learn more about this company, visit www.PlantX.com, www.PlantX.ca and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. To visit the Company’s YouTube channel, click here. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Annual growth of 17% is forecast for cannabis extraction market to reach $28.5 billion by 2027
• Pure Extracts Technologies is already operating leading extraction systems from Vitalis and will soon become one of the first companies to have Vitalis’ new Cosolvent Injection System (“CIS”)
• The CIS delivers dramatically faster throughput capacities, even higher-quality cannabis extracts, optimal ethanol cosolvent flow rates and low ethanol usage

Analysts are aligned on the future of the cannabis extraction market, with expectations for years of double-digit compound annual growth rates. The market experts at Grand View Research see 16.6% CAGR for the market to reach $28.5 billion by 2027 (https://ibn.fm/OSkhQ). Market Insight Reports concurs with the trajectory, seeing the market at $26.1 billion in the next six years (https://ibn.fm/L1IsE). Drivers are another common thread, particularly in medical applications where consumers and scientists continue to expand their understanding of all the healthcare uses for the spate of compounds found in cannabis and hemp plants. That’s good news to extraction companies like Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) that get those compounds, called cannabinoids, out of the plant. The methods for extracting cannabinoids vary, as do the end products. Generally speaking, there are three types of products: full-spectrum, distillates and isolates. Full-spectrum products contain all the cannabinoids found in cannabis while distillates offer higher purity of either THC or CBD, depending on the biomass source.  Isolates are made up of only ultra-pure CBD or THC and no other cannabis compounds. Full-spectrum products are the most popular because of what is known as the “entourage effect,” delivered with the full gamut of cannabinoids. For many people dealing with common ailments like anxiety and pain, cannabinoids are becoming a go-to alternative to traditional pharmaceuticals. Pure Extracts this month ordered brand-new technology from Vitalis, a global leader in extraction systems, to stay on the leading edge of the industry as demand increases. The British Columbia-based Company ordered Vitalis’ state-of-the-art Cosolvent Injection System (“CIS”), meaning Pure Extracts will be one of the first companies in the world to receive the innovative system. The CIS is an add-on that enhances Vitalis carbon dioxide extraction systems, including the Q90 (Vitalis’ flagship product) and R200 (Vitalis’ “massive volume” series) systems currently used at Pure Extracts’ facilities (https://ibn.fm/M1aIT). The CIS provides dramatically faster throughput capacities while maintaining the quality of the cannabis and hemp extracts. Furthermore, the Vitalis CIS has been designed to achieve the optimal ethanol cosolvent flow rate ranges for both cannabis and hemp extracts (i.e., THC and CBD), balancing extract quality with efficiency while keeping ethanol usage exceptionally low. To operators, this translates to better product, more product and higher margins. “We are very excited to be one of the first recipients of the Vitalis Cosolvent Injection System,” said Pure Extracts CEO Ben Nikolaevsky in a news release on the order (https://ibn.fm/hfae2). “It will allow us to ramp-up our production much faster than we had anticipated allowing us to offer our customers exceptional value while still producing the same high-quality oil extracts we are known for,” he concluded. For more information, visit the company’s website at www.PureExtractsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• FingerMotion’s current offerings includes telecommunications products and services, SMS and MMS services, Big Data Insights (Sapientus) and a Rich Communication Services (“RCS”) platform
• The global telecom industry reached $1.74 trillion in 2019 and was forecast to grow at a CAGR of 5% from 2020 to 2027
• The insurtech market was valued at $2.72 billion for 2020 and is expected to grow at a CAGR of 48.8% during the forecast period from 2021 to 2028. FingerMotion’s proprietary platform, Sapientus, is poised to leverage demand for mobile insurance in the Chinese market
• The company’s Rich Communication Services platform will provide additional resources for businesses and brands in China looking to increase their communications networks and leverage 5G technology
• The company’s management team is made up of individuals who are highly experienced in finance and Big Data, including multiple entrepreneurs who have successfully founded their own companies

FingerMotion (OTCQX: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users. Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City. Current Offerings FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

• Telecommunications Products and Services– FingerMotion’s proprietary universal exchange platform, PigeonHole Integration System (“PIS”), offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
• SMS and MMS Services– The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights– FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
• Rich Communication Services (“RCS”)– FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (“IoT”) applications. The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9). In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D). Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities. Management Team Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia. Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (“MIA”) and an Associate Member of the Chartered Institute of Management Accountants, UK (“ACMA”). Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• AmpliTech Group, Inc. receives over $500,000 of orders from a major defense contractor and a leading satellite broadcaster
• AMPG subsidiary, Specialty Microwave, received a $190,000 order from a leading broadcaster
• AMPG also received a $366,000 order from a major defense contractor for the METIS Program
• With increased demand, Amplitech’s backlog has now reached a record $2.2 million

AmpliTech Group (NASDAQ: AMPG, AMPGW), the provider of industry-leading SATCOM Low Noise Amplifier Solutions for the past 18 years, designs and develops top-quality microwave amplifiers using its experience, technical expertise, and superior design knowledge. AmpliTech announced that the company has received orders worth $500,000 from a major Fortune 100 defense contractor and a major satellite and cable TV broadcaster. The company’s subsidiary, Specialty Microwave, acquired in 2019, is a satellite communications (SATCOM) products company. They received a $190,000 order from a leading broadcaster that will use Specialty Microwave’s unique equipment to process satellite ground station signals behind the antennas. Further, AMPG also received a $366,000 order for its premium low noise amplifiers from a major defense contractor in support of the METIS Program (https://ibn.fm/SMVJN). Fawad Maqbool, the CEO and founder of Ampliteh Group, said that the company was very pleased to receive these orders that reflect the rapidly-increasing demand for high-performance products and its expansion into mainstream emerging technology applications. He went on to say that the demand has remained “pent-up” due to the COVID-19 pandemic, and that they expect bookings to increase in the 2^nd half of the year. With the growing demand for the company’s products, AMPG reached a record backlog this year. Amplitech announced that its backlog reached $2.2 million at the end of the Q1 of 2021. Fawad stated that the growing backlog indicates the increasing demand and revenues in the upcoming quarters. To meet the skyrocketing demands, the company is geared towards strengthening its management team and resources as outlined in the S-1 filing and the recent $11 million capital raise by AMPG. Amplitech is well-positioned and equipped with the necessary funds to expand the company’s disruptive technology base, generate increased revenues, and capture greater volumes of its target technology market sectors (https://ibn.fm/liGen). The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. AmpliTech also has developed new products for the 5G/6G wireless ecosystem and infrastructure. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

• Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed
• A recent study by the Washington University School of Medicine found that the length of survivability appeared to improve when the standard chemotherapy regimen was given in the morning instead of the evening
• Brain cancer drug developer CNS Pharmaceuticals is also working on a solution to improve the quality of GBM care, seeing hope in its lead drug candidate, Berubicin, which showed promise in a small Phase 1 trial nearly 15 years ago
• One patient from that Phase 1 trial was still alive and cancer-free as of the most recent assessment in November
• CNS expects to begin a larger, multi-center potentially pivotal trial imminently (as well as collaborating on two Polish trials conducted by sublicensee partner WPD Pharmaceuticals), comparing Berubicin’s performance to the chemotherapy drug lomustine in hundreds of patients at nearly 60 oncology centers around the world

A new study recently completed by the Washington University School of Medicine in St. Louis has found that glioblastoma (“GBM”) brain cancer patients receiving the current chemotherapy standard of care had longer survivability rates if they switched from receiving treatments in the evening to receiving the treatments in the morning — encouraging news for patients with the incurable illness, as well as for neuro-oncology researchers attempting to develop improved treatments, including biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP). “In my lab, we were studying daily rhythms in astrocytes, a cell type found in the healthy brain. We discovered some cellular events in healthy cells varied with time of day,” professor of biology Erik D. Herzog, PhD, stated in a Science Daily report on the study Herzog co-authored with professor of pediatrics and of neuroscience Joshua B. Rubin, MD, PhD (https://ibn.fm/TisXR). “Working with Dr. Rubin, we asked if glioblastoma cells also have daily rhythms. And if so, does this make them more sensitive to treatment at certain times?” Herzog said. “Very few clinical trials consider time of day even though they target a biological process that varies with time of day and with a drug that is rapidly cleared from the body. We will need clinical trials to verify this effect, but evidence so far suggests that the standard-of-care treatment for glioblastoma over the past 20 years could be improved simply by asking patients to take the approved drug in the morning.” GBM patients currently have an average 15-month survival rate after diagnosis of the illness. The Washington University study’s benefits were small — those who received the drug in the morning had an overall survival of about 17 months, while those who received it in the evening had an overall survival of about 13.5 months. But scientists hail any potentially significant increase in survivability as a step in the right direction for treating an incurable disease. Furthermore, among a subset of patients with what are called MGMT methylated tumors, the study’s participants who took the drug in the morning averaged overall survival of about 25.5 months compared to 19.5 months — a difference of six months — for those who were medicated in the evening, the study’s authors reported. CNS Pharmaceuticals is working to determine the efficacy of its lead drug candidate, Berubicin, in fighting off glioblastomas. In a small Phase 1 trial completed by another company well over a decade ago, 44 percent of patients saw their disease stabilize or improve. One Berubicin patient emerged cancer-free and as of the most recent medical assessment in November was still alive and still in remission nearly 15 years after the Phase 1 trial (https://ibn.fm/yZACY). CNS now hopes to advance Berubicin to commercial production, with the start of its potentially pivotal clinical trial slated to begin this quarter. The global trial will compare Berubicin’s response to the effectiveness level of established chemotherapy drug lomustine in 243 GBM patients at about 35 clinical sites in the United States (https://ibn.fm/x8Zp2) and 25 more in foreign locations. The company’s sublicensee partner, WPD Pharmaceuticals, will begin a similar Phase 2 clinical trial of Berubicin in Poland during the second quarter, with interim results anticipated by year’s end or early first quarter of 2022. WPD will also launch a Berubicin trial involving pediatric patients sometime later this year — the first significant investigation involving children with malignant gliomas (https://ibn.fm/CjWPj). Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers. … However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain,” CNS CEO John Climaco said in a webinar late last year (https://ibn.fm/d2OFK). “Berubicin may change that history because it is the first anthracycline that, based on limited clinical data, appears to cross the blood-brain barrier and achieve drug levels critical for efficacy against central nervous system malignancies.” For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP